Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo
nivolumab · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with resectable non-small cell lung cancer measuring at least 4 cm or node positive, without known EGFR mutations or ALK rearrangements; nivolumab plus platinum-doublet chemotherapy before surgery, then nivolumab alone after surgery.
LAMPGEN ANALYSIS
Why it matters
This approval added a postoperative nivolumab phase to the preoperative combination for the defined resectable population.
What research teams should watch
Keep resectability, biomarker exclusions and postsurgical recovery criteria visible to both surgical and medical oncology teams.
PRIMARY RECORDS